Page 89 - Read Online

Page 10 of 12 Bongiovanni et al. J Cancer Metastasis Treat 2022;8:44 https://dx.doi.org/10.20517/2394-4722.2022.78

Copyright
© The Author(s) 2022.

REFERENCES
1. Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol 2010;5:1841-8. DOI
PubMed
2. Beasley MB, Galateau-Salle F, Dacic S. Pleural mesothelioma classification update. Virchows Arch 2021;478:59-72. DOI PubMed
3. Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the
consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med 2018;142:89-108. DOI PubMed
4. Viscardi G, Di Liello R, Morgillo F. How I treat malignant pleural mesothelioma. ESMO Open 2020;4:e000669. DOI
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone
in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44. DOI PubMed
6. Zalcman G, Mazieres J, Margery J, et al. French cooperative thoracic intergroup (IFCT), bevacizumab for newly diagnosed pleural
mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open- label, phase 3 trial.
Lancet 2016;387:1405-14. DOI PubMed
7. Scagliotti GV, Gaafar R, Nowak AK, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients
with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet
Respir Med 2019;7:569-80. DOI PubMed
8. Davis AP, Kao SC, Clarke SJ, Boyer M, Pavlakis N. Emerging biological therapies for the treatment of malignant pleural
mesothelioma. Expert Opin Emerg Drugs 2021;26:179-92. DOI PubMed
9. Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. TIGIT, the next step towards successful combination immune checkpoint
therapy in cancer. Front Immunol 2021;12:699895. DOI PubMed PMC
10. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
(CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375-86. DOI PubMed
11. Yap TA, Nakagawa K, Fujimoto N, et al. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-
label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med 2021;2021:S2213260020305154. DOI PubMed
12. Okada M, Kijima T, Aoe K, et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, japanese
phase ii study in malignant pleural mesothelioma (MERIT). Clin Cancer Res 2019;25:5485-92. DOI PubMed
13. Calabrò L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an
open-label, single-arm, phase 2 trial. Lancet Oncol 2013;14:1104-11. DOI PubMed
14. Calabrò L, Ceresoli GL, di Pietro A, et al. CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target
therapy? Cancer Immunol Immunother 2015;64:105-12. DOI PubMed
15. Calabrò L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant
malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med 2015;3:301-9. DOI PubMed
16. Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma
(DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol
2017;18:1261-73. DOI PubMed
17. Calabrò L, Ceresoli GL, D’Incecco A, Scherperee A, Aerts J, Maio M. Immune checkpoint therapy of mesothelioma: pre-clinical bases
and clinical evidences. Cytokine Growth Factor Rev 2017;36:25-31. DOI PubMed
18. Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed death 1 blockade with nivolumab in patients with recurrent
malignant pleural mesothelioma. J Thorac Oncol 2018;13:1569-76. DOI PubMed
19. Hassan R, Thomas A, Nemunaitis JJ, et al. Efficacy and safety of avelumab treatment in patients with advanced unresectable
mesothelioma: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol 2019;5:351-7. DOI PubMed PMC
20. Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma
(KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 2017;18:623-30. DOI
PubMed
21. Fujimoto N, Okada M, Kijima T, et al. Clinical efficacy and safety of nivolumab in Japanese patients with malignant pleural
mesothelioma: 3-year results of the MERIT study. JTO Clin Res Rep 2021;2:100135. DOI PubMed PMC
22. Popat S, Curioni-Fontecedro A, Dafni U, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent
chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15)
PROMISE-meso trial. Ann Oncol 2020;31:1734-45. DOI PubMed
23. Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma
(CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2021;22:1530-40. DOI PubMed PMC
24. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer
therapy. Nat Rev Cancer 2016;16:275-87. DOI PubMed PMC
25. Chen J, Li S, Yao Q, et al. The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a
systematic review and meta-analysis. World J Surg Oncol 2020;18:150. DOI PubMed PMC
26. Arru C, De Miglio MR, Cossu A, et al. Durvalumab plus tremelimumab in solid tumors: a systematic review. Adv Ther 2021;38:3674-